Clover Health Investments (CLOV) 2026 Jefferies Healthcare Services and Technology Conference summary
Event summary combining transcript, slides, and related documents.
2026 Jefferies Healthcare Services and Technology Conference summary
15 Sep, 2026Business model and differentiation
Operates a proprietary technology platform, Clover Assistant, enabling both in-network and employed clinicians to engage members at the point of care.
Maintains full risk on its entire population, not delegating risk to downstream providers.
Focuses on the PPO market, with 98% of members enrolled in PPO plans, and is structured to succeed where others are exiting.
High member retention above 95% is driven by benefit stability and technology-enabled engagement.
Industry trends and market environment
Industry is experiencing pricing discipline and benefit stability, especially for 2026 and 2027, as a response to recent volatility.
National players are shifting away from $0 PPO offerings, with continued exits expected into 2027.
Selective disruption is anticipated in specific geographies, rather than nationwide.
Utilization and margin outlook
Inpatient and skilled nursing facility utilization trends are favorable, while outpatient trend pressures have moderated since March.
Margin recovery is expected to be driven by pricing discipline and benefit design changes, leading to increased member shopping and growth.
Cohort maturation is a key driver, with $70 and $85 per member per month gross profit increases from year one to two and two to three, respectively.
Latest events from Clover Health Investments
- Favorable trends and cohort maturation underpin strong 2027 growth expectations.CLOV
UBS Global Healthcare Conference - Q3 growth and higher FY2026 guidance support profitability and 2027 earnings expansion.CLOV
Q3 2026 - AI-powered, proactive care and strong retention fuel rapid growth and profitability in Medicare Advantage.CLOV
Canaccord Genuity's 46th Annual Growth Conference - AI-driven care model achieves profitability, top quality ratings, and better outcomes for chronic disease.CLOV
Investor presentation - Q2 2026 saw 56% revenue growth, $28M net income, and raised full-year guidance.CLOV
Q2 2026 - Strong growth, improved clinical outcomes, and 2026 profitability target driven by AI technology.CLOV
Citi Annual Global Healthcare Conference 2025 - First-ever GAAP net profit and raised guidance on strong revenue, margin, and Star rating gains.CLOV
Q2 2024 - Tech-driven growth and strategic expansion fueled record revenue and profitability gains.CLOV
Bank of America 2025 Healthcare Conference - AI-driven platform fueled record growth, top quality scores, and profitability for continued expansion.CLOV
43rd Annual J.P. Morgan Healthcare Conference 2025